Group 1 - Eddie Pharmaceutical's stock increased by 5.12%, reaching 17.86 CNY per share, with a trading volume of 74.09 million CNY and a turnover rate of 1.02%, resulting in a total market capitalization of 7.515 billion CNY [1] - The company, established on December 15, 2009, and listed on July 20, 2020, is located in Yangzhou, Jiangsu Province, and focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The revenue composition of Eddie Pharmaceutical includes human-derived proteins at 41.11%, new drugs at 35.69%, diagnostic equipment, reagents, and others at 13.62%, generic drugs at 9.47%, and other supplementary products at 0.11% [1] Group 2 - Among the top ten circulating shareholders of Eddie Pharmaceutical, a fund under Huatai-PineBridge holds 4.6607 million shares, accounting for 1.11% of the circulating shares, with an estimated floating profit of approximately 4.0548 million CNY [2] - The Huatai-PineBridge Medical Health Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.486 billion CNY, achieving a year-to-date return of 10.43% and a one-year return of 41.9% [2] - The fund ranks 654 out of 8838 in year-to-date performance and 3211 out of 8089 in one-year performance, with a cumulative return of 171.57% since inception [2]

Group 1 - The core point of the article highlights the stock performance of Yinos, which increased by 5.19% to reach a price of 58.18 CNY per share, with a trading volume of 181 million CNY and a turnover rate of 3.57%, resulting in a total market capitalization of 8.202 billion CNY [1] - Yinos is a biotechnology company based in the China (Shanghai) Free Trade Zone, established on May 12, 2010, and listed on September 3, 2024. The company primarily provides non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services, 3.42% from clinical services, and 0.27% from other sources [1] Group 2 - Among the top ten circulating shareholders of Yinos, a fund under Huatai-PineBridge is noted, specifically the Huatai-PineBridge Healthcare Mixed Fund (470006), which entered the top ten shareholders in the third quarter with 1.1215 million shares, accounting for 1.24% of circulating shares. The estimated floating profit for today is approximately 3.2188 million CNY [2] - The Huatai-PineBridge Healthcare Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.486 billion CNY. Year-to-date returns are 6.72%, ranking 749 out of 8825 in its category, while the one-year return is 36.03%, ranking 3440 out of 8084. Since its inception, the fund has achieved a return of 162.46% [2] - The fund manager of Huatai-PineBridge Healthcare Mixed Fund is Zheng Lei, who has a cumulative tenure of 11 years and 26 days. The total asset scale under his management is 8.093 billion CNY, with the best fund return during his tenure being 53.42% and the worst being -35.19% [2]

Group 1 - Eddie Pharmaceuticals (688488.SH) reported its Q3 2025 results on October 31, 2025, with 13 institutional investors holding a total of 216 million shares, representing 51.44% of the company's total equity [1] - The top ten institutional investors include Guangzhou Weimei Investment Co., Ltd., Weimei Investment (Hong Kong) Co., Ltd., AEGLE TECH LIMITED, and others, collectively holding 51.23% of the shares, which is a decrease of 1.26 percentage points from the previous quarter [1] Group 2 - In the public fund sector, one fund, the Xingquan Business Model Mixed (LOF) A, increased its holdings by 0.64% compared to the previous period [2] - Three public funds reduced their holdings, including Penghua Medical Technology Stock A, with a total decrease of 0.65% [2] - Three new public funds disclosed their holdings this period, including Huatai-PineBridge Medical Care Mixed, Yongying Medical Health A, and Hongtu Innovation Medical Care Stock [2]